Blog | diligentiastrategy

What Does The Scrutiny on Orphan Drug Pricing Mean For Manufacturers and Consumers?

Ongoing changes in U.S. healthcare reform and the Congressional inquiry into the Orphan Drug Act’s effect on drug pricing have created a...

Rare Disease Day

Diligentia honors the 10th anniversary of International Rare Disease Day taking place on February 28, 2017. Originally established by...

International Conference on Rare Diseases and Orphan Drugs Announces New Board of Directors

Diverse body of expertise to tackle the challenges of rare diseases (Stockholm, Sweden) – November 14, 2016. The International Conference...

Meet with us at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco January 9-12, 201

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email...

What is the impact of rare diseases on individuals and health care systems?

Congressionally funded report details diagnostic challenges and costs of rare diseases in the US

Diagnostics: Moving to the forefront of Global Healthcare

Economic Burden of Rare Diseases Nearly $1 Trillion

CBO Comparison of Brand-Name Drug Prices Among Selected Federal Programs

Orphan drugs account for more than half of all FDA drug approvals in 2020

Rare Disease Stakeholders: Do mRNA COV19 Vaccines Affect Eligibility to Receive Future Gene Therapy?

How do we identify and measure value for patients with rare diseases?

National Burden of Rare Disease Survey

HVH Precision Analytics and Diligentia Strategy Announce Upcoming Presentation at the 2020 American